Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps

Program Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

Credit Expired

Target Audience

The target audience for this activity is US-based allergy-immunology, ENT, and pulmonology clinicians (physicians, NPs, and PAs) who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (and/or comorbid asthma).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Accurately diagnose patients with type 2 inflammation-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
Evaluate emerging agents for CRSwNP based on their efficacy and safety data

Activity Faculty

Joseph K. Han, MD

Professor
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
Norfolk, VA

Featured RMEI CE Activities – Earn CE Credit(s)

Sniffing Out the Problem: A Dive into Management for Chronic Rhinosinusitis with Nasal Polyps

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Joseph K. Han, MD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe